Premium
MicroRNA‐193a and taxol combination: A new strategy for treatment of colorectal cancer
Author(s) -
Hejazi Maryam,
Baghbani Elham,
Amini Mohammad,
Rezaei Tayebeh,
Aghanejad Ayuob,
Mosafer Jafar,
Mokhtarzadeh Ahad,
Baradaran Behzad
Publication year - 2020
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29374
Subject(s) - microrna , cancer research , metastasis , cell cycle , downregulation and upregulation , cell growth , colorectal cancer , apoptosis , viability assay , biology , cancer , gene , biochemistry , genetics
Micro RNAs (miRNAs) show a considerable promise as a therapeutic agent for combination therapy of colorectal cancer (CRC). Given that, the current study was purposed to explore the potential therapeutic role and underlying mechanism of miR‐193a as a promising tumor suppressor in human CRC cell lines in combination with Taxol. Therefore, HT‐29 cells with the lowest expression levels of miR‐193a were treated with miR‐193a mimics and Taxol, separately or in combination. Functional analyses showed that the combination therapy inhibited migration and colony formation of HT‐29 cells and arrested the cell cycle at the G1 phase. Moreover, treatment with Taxol reduced cell survival with an increase in mRNA expression of metastasis‐related genes caspase‐3 and caspase‐9, whereas miR‐193a transfection alone didn't significantly influence cell viability and apoptosis induction. Quantitative reverse transcription polymerase chain reaction results also revealed that miR‐193a replacement decreased the expression levels of c‐Myc, MMP‐9, vimentin, and ROCK in treatment groups compared to the controls. Therefore, it could be concluded miR‐193a inactivates cell migration via suppression of metastasis pathways in CRC and through downregulation of c‐Myc, acts as a negative regulator of cell cycle and growth. Then, our findings imply that miR‐193a replacement combined with Taxol chemotherapy could be considered as a new potential therapeutic approach for improvement of CRC treatment.